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Effect of Ejection Fraction on Clinical
Outcomes in Patients Treated With
Omecamtiv Mecarbil in GALACTIC-HF
John R. Teerlink, MD,a Rafael Diaz, MD,b G. Michael Felker, MD, MHS,c John J.V. McMurray, MD,d Marco Metra, MD,e
Scott D. Solomon, MD,f Tor Biering-Sørensen, MD, PHD, MPH,g Michael Böhm, MD,h Diana Bonderman, MD,i
James C. Fang, MD,j David E. Lanfear, MD,k Mayanna Lund, MD,l Shin-ichi Momomura, MD,m Eileen O’Meara, MD,n
Piotr Ponikowski, MD, PHD,o Jindrich Spinar, MD, PHD,p Jose H. Flores-Arredondo, MD,q Brian L. Claggett, PHD,f
Stephen B. Heitner, MD,r Stuart Kupfer, MD,r Siddique A. Abbasi, MD,q Fady I. Malik, MD, PHD,r
on behalf of the GALACTIC-HF Investigators

ABSTRACT
BACKGROUND In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving
Contractility in Heart Failure) (n ¼ 8,256), the cardiac myosin activator, omecamtiv mecarbil, signiﬁcantly reduced the
primary composite endpoint (PCE) of time-to-ﬁrst heart failure event or cardiovascular death in patients with heart
failure and reduced ejection fraction (EF) (#35%).
OBJECTIVES The purpose of this study was to evaluate the inﬂuence of baseline EF on the therapeutic effect of
omecamtiv mecarbil.
METHODS Outcomes in patients treated with omecamtiv mecarbil were compared with placebo according to EF.
RESULTS The risk of the PCE in the placebo group was nearly 1.8-fold greater in the lowest EF (#22%) compared with the
highest EF ($33%) quartile. Amongst the pre-speciﬁed subgroups, EF was the strongest modiﬁer of the treatment effect of
omecamtiv mecarbil on the PCE (interaction as continuous variable, p ¼ 0.004). Patients receiving omecamtiv mecarbil had a
progressively greater relative and absolute treatment effect as baseline EF decreased, with a 17% relative risk reduction for the
PCE in patients with baseline EF #22% (n ¼ 2,246; hazard ratio: 0.83; 95% conﬁdence interval: 0.73 to 0.95) compared with
patients with EF $33% (n ¼ 1,750; hazard ratio: 0.99; 95% conﬁdence interval: 0.84 to 1.16; interaction as EF by quartiles,
p ¼ 0.013). The absolute reduction in the PCE increased with decreasing EF (EF #22%; absolute risk reduction, 7.4 events per
100 patient-years; number needed to treat for 3 years ¼ 11.8), compared with no reduction in the highest EF quartile.
CONCLUSIONS In heart failure patients with reduced EF, omecamtiv mecarbil produced greater therapeutic beneﬁt as baseline
EF decreased. These ﬁndings are consistent with the drug’s mechanism of selectively improving systolic function and presents an
important opportunity to improve the outcomes in a group of patients at greatest risk. (Registrational Study With Omecamtiv
Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329)
(J Am Coll Cardiol 2021;78:97–108) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oped that improve cardiovascu-
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lar outcomes in patients with

symptomatic (New York Heart Association [NYHA]

heart failure with reduced ejection fraction

functional class II to IV) HFrEF and EF #35% as per the

(HFrEF). However, none of the currently

patient’s most recent medical record within 12 months

available drugs directly improve the central

prior to screening. The most recent qualifying EF was

defect of HFrEF: reduced systolic function.

to be at least 30 days after any of the following, if

Moreover, severe impairment of systolic

applicable: 1) an event likely to decrease EF (eg,

function is often associated with lower blood

myocardial infarction, sepsis); 2) an intervention likely

pressure and greater difﬁculty tolerating

to increase EF (eg, cardiac resynchronization therapy,

target doses of guideline-directed medical therapies.

coronary revascularization); or 3) the ﬁrst ever pre-

Myotropes (1) represent a new class of drugs that

sentation for heart failure. All participants were

improve myocardial function by directly augmenting

required to have elevated natriuretic peptides (N-ter-

cardiac sarcomere function. The cardiac myosin acti-

minal pro–B-type natriuretic peptide [NT-proBNP]

vator, omecamtiv mecarbil (2,3), is the ﬁrst of this

level $400 pg/ml [1,200 pg/ml for patients in atrial

class, and it increases systolic function by selectively

ﬁbrillation] or B-type natriuretic peptide [BNP] $125

facilitating the actin-myosin interaction, increasing

pg/ml [375 pg/ml for patients in atrial ﬁbrillation]) and

contractile force without altering the cardiomyocyte

were on optimized background heart failure therapy.

calcium transient (4). In patients with chronic HFrEF

Participants were currently hospitalized for heart

enrolled in COSMIC-HF (Chronic Oral Study of Myosin

failure (inpatients) or within 1 year had either an ur-

Activation to Increase Contractility in Heart Failure),

gent visit to the emergency department for heart fail-

omecamtiv mecarbil increased left ventricular sys-

ure or a hospitalization for heart failure (outpatients).

tolic function, as reﬂected by increased systolic ejec-

Key exclusion criteria included current hemodynamic

tion time and ejection fraction (EF) and improved

or clinical instability requiring mechanical or intrave-
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myocardial strain, while decreasing left ventricular

nous medication, systolic blood pressure <85 mm Hg,

systolic and diastolic volumes, natriuretic peptide
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concentrations, and heart rate (5,6). The GALACTIC-

min/1.73 m 2, recent acute coronary syndrome events or

HF (Global Approach to Lowering Adverse Cardiac

cardiovascular procedures (including planned pro-

outcomes

in

cedures), and other conditions with reduced life

Heart Failure) trial was the ﬁrst trial to demonstrate

expectancy <2 years or that would adversely affect

a beneﬁcial effect of selectively increasing cardiac

participation in the trial. The study protocol was

contractility on cardiovascular outcomes in patients

approved by the relevant local ethics committees, and

with HFrEF (7–9). Here, we examine the impact of

all participants provided informed consent.

Through

Improving

Contractility
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baseline EF, a pre-speciﬁed subgroup, as a modiﬁer
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STUDY OUTCOMES. The primary outcome was a

composite of the time-to-ﬁrst heart failure event or
death due to cardiovascular causes. Secondary outcomes included the time to cardiovascular death;

METHODS

change in Kansas City Cardiomyopathy Questionnaire
Total Symptom Score (KCCQ-TSS) from baseline to

GALACTIC-HF STUDY DESIGN. The design, baseline

week 24 using a scale from 0 to 100, with a higher

characteristics, and primary results of the trial have

score indicating fewer symptoms; time to ﬁrst heart

been previously published (7–9). Brieﬂy, GALACTIC-

failure hospitalization; and time to all-cause death.

HF was a phase 3, global, double-blind, placebo-
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published (9). All deaths, HF events, major cardiac

or Russia; and more likely to be enrolled in the United

ischemic

infarction/unstable

States, Canada, Western Europe, South Africa, or

angina hospitalization and coronary revasculariza-

Australasia. Patients with lower EF were more likely

tion), and strokes were adjudicated by an indepen-

to have a nonischemic etiology of heart failure, NYHA

dent external Clinical Events Committee (Duke

functional class III/IV, lower body mass index, lower

Clinical Research Institute) using standardized deﬁ-

systolic blood pressure, higher heart rate, higher NT-

nitions (10).

proBNP, and higher cardiac troponin I, and were less

STATISTICAL ANALYSIS. The initial analysis plan

likely to have coronary artery disease, hypertension,

events

(myocardial

deﬁned subgroups according to median baseline EF;

type 2 diabetes mellitus, or atrial ﬁbrillation/ﬂutter.

however, for the purposes of this paper, we further

Lower EF was associated with greater symptom

evaluated baseline characteristics for patients by

burden in patients enrolled as inpatients (lower

quartiles of EF. Continuous variables were summa-

KCCQ-TSS), but there was no meaningful difference

rized via means and SDs or medians and interquartile

in the outpatients. There was no difference in the

ranges, as appropriate. Categorical variables are

proportion

summarized with counts and percentages. Tests of

([angiotensin-converting enzyme inhibitor, angio-

trend across categories were conducted via linear

tensin receptor blocker, or angiotensin receptor

regression, Cuzick’s nonparametric trend test, and

of

patients

receiving

triple

therapy

neprilysin inhibitor] þ mineralocorticoid receptor

chi-square tests of trend, respectively. Treatment ef-

antagonist þ beta-blocker) among the EF quartiles.

fects on continuous outcomes were assessed via

Patients

linear regression models adjusted for the corre-

angiotensin-receptor neprilysin inhibitor, ivabradine,

sponding baseline value of the parameter of interest.

digitalis glycosides, cardiac resynchronization ther-

with

implantable

EFs

had

higher

use

of

Survival analyses were conducted using Poisson

apy,

regression models to estimate incidence rates, rate

compared with patients with higher EFs.

differences, and rate ratios and Cox proportional

RELATIONSHIP BETWEEN EF AND CLINICAL OUTCOMES.

hazards models to estimate hazard ratios (HRs).

Within the group of patients with HFrEF enrolled in

Treatment effect HRs were adjusted for estimated

the GALACTIC-HF trial, the incidence of clinical out-

glomerular ﬁltration rate and stratiﬁed by region and

and

lower

cardioverter-deﬁbrillators

comes increased with decreasing EF (Table 2). As

inpatient status as in the primary GALACTIC-HF

noted by the rates in the placebo group, the incidence

analysis. To allow for potentially nonlinear associa-

of the primary outcome of ﬁrst heart failure event or

tions between EF and time-to-event outcomes,

cardiovascular death in patients in the lowest EF

restricted cubic splines were utilized in the Poisson

quartile (EF #22%; 35.6 per 100 patient-years) was

regression models with 3 knots. Treatment effect

almost 80% greater than in the highest EF quartile

modiﬁcation was assessed via the introduction of

(EF $33%; 20 per 100 patient-years). The incidence of

interaction terms between randomized treatment

ﬁrst heart failure event was 90% greater (28.3 events

assignment and the corresponding EF model cova-

vs 14.9 events per 100 patient-years) and of cardio-

riates (eg, linear, quartile, or cubic spline). All ana-

vascular death was 68% greater (14.1 deaths vs 8.4

lyses were conducted using STATA version 16

deaths per 100 patient-years) in the lowest EF

(StataCorp, College Station, Texas). All p values <0.05

compared to the highest EF quartile. Participants in

were considered statistically signiﬁcant. Due to the

the placebo group had signiﬁcant improvements in

exploratory nature of these analyses, no adjustments

the KCCQ-TSS at week 24 compared with baseline,

were made for multiple comparisons.

with greater improvements in those enrolled as in-

RESULTS

patients, but there was no modiﬁcation of this effect
by EF quartile (Supplemental Table 3).

STUDY PATIENTS. All of the 8,232 participants had

INFLUENCE OF EF ON THE TREATMENT EFFECT OF OME-

reported EFs with over 97% measured by echocar-

CAMTIV MECARBIL. Omecamtiv mecarbil signiﬁcantly

diogram

Supplemental

decreased the primary endpoint of the time-to-ﬁrst

Figures 1 and 2), and there were 4,456 patients with

heart failure event or cardiovascular death in the

an EF #28%, the median EF in the trial. Due to digit

overall trial population (HR: 0.92; 95% conﬁdence

(Supplemental

Table

1,

preference for EF assessment, over 70% of the pa-

interval [CI]: 0.86-0.99; p ¼ 0.025) (8). The statistical

tients had an EF #30%. When assessed by quartiles

analysis plan pre-speciﬁed the assessment of the

(Table 1, Supplemental Table 2), patients with lower

primary endpoint in the EF subgroups above and

EFs were younger; more likely to be male and non-

below the median value (#28%), and there was a

White; less likely to be enrolled in Eastern Europe

signiﬁcant modiﬁcation of the treatment effect of
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T A B L E 1 Baseline Characteristics of GALACTIC-HF Patients’ Ejection Fraction Quartiles

EF #22%
(n ¼ 2,246)

EF 23%–28%
(n ¼ 2,210)

EF 29%–32%
(n ¼ 2,026)

EF $33%
(n ¼ 1,750)

p Value

Age, yrs

62.5  11.8

64.1  11.6

65.7  10.9

66.4  10.5

<0.001

Female

422 (18.8)

451 (20.4)

455 (22.5)

421 (24.1)

<0.001

171 (7.6)

224 (10.1)

179 (8.8)

136 (7.8)
68 (3.9)

Demographics

<0.001

Race
Asian
Black or African American

243 (10.8)

156 (7.1)

95 (4.7)

Other*

200 (8.9)

162 (7.3)

118 (5.8)

83 (4.7)

White

1,632 (72.7)

1,668 (75.5)

1,634 (80.7)

1,463 (83.6)

152 (6.8)

214 (9.7)

174 (8.6)

130 (7.4)

<0.001

Geographic region
Asia
Eastern Europe/Russia

476 (21.2)

617 (27.9)

783 (38.6)

805 (46.0)

Latin and South America

438 (19.5)

504 (22.8)

364 (18.0)

268 (15.3)

United States and Canada

581 (25.9)

341 (15.4)

259 (12.8)

205 (11.7)

Western Europe/South Africa/Australasia

599 (26.7)

534 (24.2)

446 (22.0)

342 (19.5)

592 (26.4)

552 (25.0)

487 (24.0)

453 (25.9)

0.50

<0.001

Randomization setting: in-patient
Clinical characteristics
Medical conditions
Coronary artery disease

1,267 (56)

1,320 (60)

1,323 (65)

1,218 (70)

Stroke

214 (10)

194 (9)

250 (12)

161 (9)

0.80

Atrial ﬁbrillation or ﬂutter history

912 (41)

884 (40)

889 (44)

790 (45)

<0.001

Atrial ﬁbrillation or ﬂutter at screening

547 (24.4)

561 (25.4)

609 (30.1)

528 (30.2)

<0.001

Hypertension

1,431 (64)

1,483 (67)

1,503 (74)

1,367 (78)

<0.001

Type 2 diabetes mellitus

869 (39)

880 (40)

817 (40)

743 (43)

<0.001

Chronic obstructive pulmonary disease

352 (16)

360 (16)

332 (16)

301 (17)

0.21

Heart failure history
LVEF, %

20 (15, 20)

25 (25, 27)

30 (30, 31)

34 (33, 35)

N/A

Time from last HF event, months (outpatients only)

2.9 (1.6, 5.8)

3.1 (1.6, 6.1)

3.3 (1.6, 6.5)

3.4 (1.5, 6.8)

0.039

Time from last HF hospitalization, months (outpatients only)

3.0 (1.6, 5.9)

3.2 (1.6, 6.2)

3.4 (1.7, 6.6)

3.6 (1.6, 6.9)

0.043

25 (21, 30)

24 (20, 28)

22 (17, 26)

21 (17, 25)

<0.001

II

1,160 (52)

1,164 (53)

1,085 (54)

959 (55)

III

1,007 (45)

968 (44)

889 (44)

752 (43)

IV

79 (4)

78 (4)

52 (3)

39 (2)

1,033 (46)

1,153 (52)

1,141 (56)

1,088 (62)

KCCQ total symptom score

69 (48, 88)

70 (49, 88)

71 (50, 88)

69 (49, 85)

0.77

Outpatient

75 (56, 92)

75 (54, 92)

75 (56, 92)

73 (54, 90)

0.05

Inpatient

51 (29, 69)

53 (33, 73)

55 (35, 72)

54 (31, 74)

0.022

MAGGIC score
NYHA functional classiﬁcation

Ischemic heart failure etiology

0.016

<0.001

Vitals and laboratory parameters
27.9  6.3

28.2  6.2

28.9  6.0

29.1  6.1

<0.001

SBP, mm Hg

112  15

115  15

119  15

121  14

<0.001

Heart rate, beats/min

74  12

72  12

72  12

72  12

<0.001

Body mass index, kg/m2

NT-proBNP, pg/ml
hsTnI (ng/l), median (Q3)
eGFR, ml/min/1.73 m2

2,524 (1,250, 5,296) 2,035 (1,057, 4,157) 1,866 (924, 3,655) 1615 (755, 3,245) <0.001
31 (58)

29 (55)

26 (48)

23 (43)

<0.001

59 (44, 74)

59 (44, 75)

59 (43, 74)

58 (45, 74)

0.72

Continued on the next page

omecamtiv mecarbil by EF (interaction p ¼ 0.004).

by quartiles of EF of the modifying effect on the pri-

This signiﬁcant interaction persisted (p ¼ 0.009) after

mary composite endpoint (interaction p ¼ 0.013)

further adjustment for all potential effect modiﬁers

(Table 2, Supplemental Figure 3) by treatment with

reported previously as pre-speciﬁed subgroups (8). In

omecamtiv mecarbil demonstrated a 15% (HR: 0.85;

patients with EF #28%, there was a 16% reduction in

95% CI: 0.74-0.97; p ¼ 0.016) and 17% (HR: 0.83;

the time-to-ﬁrst heart failure event or cardiovascular

95% CI: 0.73-0.95; p ¼ 0.005) relative risk reduction in

death (HR: 0.84; 95% CI: 0.77-0.92; p ¼ 0.0003)

the lower 2 quartiles of EF, respectively, compared

compared with no difference in patients with EF

with no difference in the upper 2 quartiles. Analysis

>28% (HR: 1.04; 95% CI: 0.94-1.16; p ¼ 0.45). Analysis

of EF as a continuous variable demonstrated a
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T A B L E 1 Continued

EF #22%
(n ¼ 2,246)

EF 23%–28%
(n ¼ 2,210)

EF 29%–32%
(n ¼ 2,026)

EF $33%
(n ¼ 1,750)

p Value

1,900 (85)

1,933 (88)

1,787 (88)

1,539 (88)

<0.001

534 (24)

468 (21)

351 (17)

248 (14)

<0.001

2,086 (93)

2,101 (95)

1,922 (95)

1,655 (95)

0.022

MRA

1,715 (76)

1,792 (81)

1,585 (78)

1,305 (75)

0.10

(ACEi, ARB, or ARNi) þ MRA þ BB

1,413 (63)

1,511 (68)

1,387 (68)

1,114 (64)

0.37

Digitalis glycosides

450 (20)

380 (17)

304 (15)

251 (14)

<0.001

Medications and cardiac devices
ACEi, ARB, or ARNi
ARNi
BB

SGLT2 inhibitors

64 (3)

67 (3)

44 (2)

43 (3)

0.19

Ivabradine

172 (8)

165 (8)

106 (5)

90 (5)

<0.001

Cardiac resynchronization therapy

454 (20)

321 (15)

231 (11)

152 (9)

<0.001

Implantable cardioverter-deﬁbrillator

972 (43)

745 (34)

534 (26)

363 (21)

<0.001

Values are mean  SD, n (%), or median (Q1, Q3), unless otherwise indicated. *Includes American Indian or Alaska Native, Native Hawaiian or Other Paciﬁc Islander, or multiple self-identiﬁed
races.
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ARNi ¼ angiotensin receptor-neprilysin inhibitor; BB ¼ beta-blocker; CRT ¼ cardiac resynchronization
therapy; ED ¼ emergency department; eGFR ¼ estimated glomerular ﬁltration rate; hsTnI ¼ high-sensitivity troponin I; ICD ¼ implantable cardioverter-deﬁbrillator; KCCQ ¼ Kansas City
Cardiomyopathy Questionnaire; LVEF ¼ left ventricular ejection fraction; MAGGIC ¼ Meta-Analysis Global Group in Chronic HF; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ Nterminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure; SGLT2 ¼ sodium-glucose co-transporter 2.

progressively larger treatment effect of omecamtiv

increased disproportionately between the placebo

mecarbil with decreasing EF (interaction p ¼ 0.004)

and omecamtiv mecarbil treatment groups with lower

(Central Illustration A, Table 2). The difference in the

EFs (Central Illustration B), such that absolute risk

incidence

reduction

of

the

primary

composite

endpoint

by

omecamtiv

mecarbil

progressively

T A B L E 2 Clinical Outcomes

Omecamtiv Mecarbil

Placebo

n/N (%)

Rate
(per 100 patient-yrs)

n/N (%)

Rate
(per 100 patientyrs)

EF $33%

298/892 (33)

20.5

280/858 (33)

20.0

0.99 (0.84–1.16)

0.4

EF 29%–32%

375/1,015 (37)

23.8

356/1,011 (35)

22.4

1.11 (0.96–1.28)

1.4

EF 23%–28%

393/1,086 (36)

24.0

449/1,124 (40)

27.2

0.85 (0.74–0.97)

3.3

457/1,127 (41)

28.3

522/1,119 (47)

35.6

0.83 (0.73–0.95)

7.4

236/892 (26)

16.2

208/858 (24)

14.9

1.04 (0.86–1.25)

1.3

EF 29%–32%

286/1,015 (28)

18.2

269/1,011 (27)

16.9

1.13 (0.96–1.33)

1.3

EF 23%–28%

304/1,086 (28)

18.5

345/1,124 (31)

20.9

0.84 (0.72–0.98)

2.4

351/1,127 (31)

21.7

414/1,119 (37)

28.3

0.81 (0.70–0.93)

6.6

EF $33%

228/892 (26)

15.5

201/858 (23)

14.3

1.03 (0.85–1.24)

1.2

EF 29%–32%

279/1,015 (27)

17.6

251/1,011 (25)

15.5

1.19 (1.01–1.42)

2.1

EF 23%–28%

295/1,086 (27)

17.8

327/1,124 (29)

19.6

0.86 (0.74–1.01)

1.8

EF #22%

340/1,127 (30)

20.9

400/1,119 (36)

26.9

0.82 (0.71–0.94)

6.1

153/892 (17)

9.0

136/858 (16)

8.4

1.06 (0.84–1.33)

0.6

EF 29%–32%

196/1,015 (19)

10.5

162/1,011 (16)

8.5

1.26 (1.02–1.55)

2.0

EF 23%–28%

207/1,086 (19)

10.8

235/1,124 (21)

11.8

0.88 (0.73–1.07)

1.0

EF #22%

252/1,127 (22)

13.0

265/1,119 (24)

14.1

0.96 (0.80–1.14)

1.1

Outcome by EF Quartiles

ARR
(per 100 patient-yrs)

Interaction p ¼ 0.013

Primary outcome

EF #22%

HR (95% CI)

Interaction p ¼ 0.004

First HF event
EF $33%

EF #22%

Interaction p ¼ 0.004

First HF hospitalization

Interaction p ¼ 0.14

CV death
EF $33%

Interaction p ¼ 0.38

All-cause death
EF $33%

200/892 (22)

11.8

189/858 (22)

11.7

0.98 (0.80–1.20)

0.1

EF 29%–32%

260/1,015 (26)

13.9

226/1,011 (22)

11.9

1.19 (0.99–1.42)

2.0

EF 23%–28%

278/1,086 (26)

14.4

315/1,124 (28)

15.8

0.89 (0.76–1.05)

1.4

EF #22%

329/1,127 (29)

17.0

335/1,119 (30)

17.8

0.98 (0.84–1.14)

0.8

CI ¼ conﬁdence interval; CV ¼ cardiovascular; EF ¼ ejection fraction; HF ¼ heart failure; HR ¼ hazard ratio.
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C E NT R AL IL L U STR AT IO N Primary Composite Endpoint

B

1.5

Incidence Rate
(per 100 Patient-Years)

Treatment Effect (Ratio)

A

1.25
1
.8
.6

60
50

Placebo

40

.5

30
20 Omecamtiv mecarbil

10
10

15

20
25
30
Ejection Fraction (%)

35

10

15

20
25
30
Ejection Fraction (%)

35

C
Rate Difference
(per 100 Patient-Years)

10
0
−10
−20
−30
10

15

20
25
30
Ejection Fraction (%)

35

Teerlink, J.R. et al. J Am Coll Cardiol. 2021;78(2):97–108.

Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (solid line) (dashed line, 95% conﬁdence interval) demonstrated
the increasing beneﬁcial relative treatment effect of omecamtiv with decreasing ejection fraction for the primary composite endpoint of time-to-ﬁrst heart failure or
cardiovascular death event (interaction p ¼ 0.004 by ejection fraction as continuous variable) (A). Incidence rates (B) (events/100 patient-years) of primary composite
endpoint increased with decreasing ejection fraction in both the placebo (blue lines) and omecamtiv mecarbil group (purple lines). Omecamtiv mecarbil progressively
increases the absolute rate reduction in the primary composite endpoint with decreasing ejection fraction (C).

increased with decreasing EF (Central Illustration C).

treatment effect (interaction p ¼ 0.004 by EF quartile,

In the lowest EF quartile, omecamtiv mecarbil resul-

interaction p ¼ 0.001 by EF as continuous variable)

ted in an absolute reduction of 7.4 events per 100

(Table 2). Ejection fraction had a similar modifying

patient-years, with a number-needed-to-treat of 11.8

effect on the progressive reduction of heart failure

patients over 3 years necessary to prevent an event

hospitalizations by omecamtiv mecarbil (interaction

(Table 2), compared with no reduction in the highest

p ¼ 0.004 by EF quartile, interaction p ¼ 0.001 by EF

EF quartile.

as continuous variable) (Figure 1A, Table 2). Consis-

The beneﬁcial effect of treatment with omecamtiv

tent with the primary composite endpoint, the inci-

mecarbil on the primary outcome was driven pre-

dence rate of heart failure hospitalizations increases

dominantly by the signiﬁcant reduction in heart fail-

with decreasing EF in both the placebo and ome-

ure events, and EF was a signiﬁcant modiﬁer of this

camtiv mecarbil–treated patients (Figure 1B), but was
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F I G U R E 1 Heart Failure Hospitalizations

B

1.5
1.25

Incidence Rate
(per 100 Patient-Years)

Treatment Effect (Ratio)

A

1
.8
.6
.5

60
50
40

Placebo

30
20
Omecamtiv mecarbil
10

10

15

25
30
20
Ejection Fraction (%)

35

10

15

20
25
30
Ejection Fraction (%)

35

Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (interaction p ¼ 0.001 by ejection fraction as continuous variable)
(solid line) (dashed line, 95% conﬁdence interval) demonstrated the increasing beneﬁcial relative treatment effect of omecamtiv with decreasing ejection fraction for
the time-to-ﬁrst heart failure hospitalization (A). Incidence rates (B) (events/100 patient-years) of heart failure hospitalizations increased with decreasing ejection
fraction in both the placebo (blue lines) and omecamtiv mecarbil group (purple lines).

signiﬁcantly affected by treatment with omecamtiv

showed only a 3% change (p ¼ 0.54; interaction

mecarbil, and showed a progressively greater reduc-

p < 0.001) (Table 3). Omecamtiv mecarbil treatment

tion in the absolute difference with decreasing EF. EF

resulted in a small reduction in heart rate (treatment

signiﬁcantly modiﬁed the treatment of effect of

difference of 1.1 to 1.9 beats/min across the EF quar-

omecamtiv mecarbil on total heart failure events and

tiles) and increase in troponin I (median 3 to 5 ng/l

hospitalizations as well (interaction p ¼ 0.006 and p ¼

across the EF quartiles; limit of detection, 6 ng/l;

0.009, respectively) (Supplemental Table 4). Ome-

upper reference limit 40 ng/l), which did not differ by

camtiv mecarbil had no overall effect on cardiovas-

EF quartile. There was no signiﬁcant effect on systolic

cular death, either in the overall population or as a

blood pressure, serum potassium, or creatine across

function of baseline EF (interaction p ¼ 0.14 by EF

the EF quartiles compared with placebo. There were

quartile) (Figure 2A, Table 2). As expected, the inci-

also no signiﬁcant differences noted in the incidence

dence of cardiovascular death increased comparably

of adverse events between the omecamtiv mecarbil

in both the placebo and omecamtiv mecarbil arms

and placebo-treated groups, except for an apparent

with decreasing EF (Figure 2B, Table 2). Similarly,

reduction in the incidence of adjudicated stroke for

there was no effect of omecamtiv mecarbil on all-

patients treated with omecamtiv mecarbil (Table 4).

cause mortality (Table 2). The proportional hazards
assumption was evaluated for all HRs presented in
Table 2 via a test of Schoenfeld residuals. No signiﬁcant violations were detected (all p > 0.20).

DISCUSSION
In the GALACTIC-HF trial, selectively increasing systolic function in patients with HFrEF improved car-

OTHER OUTCOMES AND SAFETY OF OMECAMTIV

diovascular outcomes (primary composite endpoint

MECARBIL BY EF. Despite the reduction in heart

HR: 0.92; p ¼ 0.025), predominantly through reducing

failure events with omecamtiv mecarbil, there was no

heart failure events (8). Given the unique mechanism

consistent beneﬁcial effect on symptoms as a func-

of action of omecamtiv mecarbil, we investigated the

tion of EF as assessed by the KCCQ-TSS in either the

inﬂuence of EF on the observed treatment effects.

subjects enrolled from the inpatient or outpatient

Omecamtiv mecarbil provided progressively greater

settings. However, there was a greater reduction in

beneﬁt by reducing heart failure events in patients

NT-proBNP by omecamtiv mecarbil in patients with

with lower baseline EF such that patients with an EF

lower EF such that the lowest EF quartile had a 22%

below the median (#28%) had an 16% reduction in the

reduction (p < 0.001), whereas the highest EF quartile

primary

endpoint.

We

also

observed

greater
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F I G U R E 2 Cardiovascular Death

B

1.5

Incidence Rate
(per 100 Patient-Years)

Treatment Effect (Ratio)

A

1.25
1
.8
.6

30
20

10

Placebo

Omecamtiv mecarbil

.5
10

15

25
30
20
Ejection Fraction (%)

35

10

15

20
25
30
Ejection Fraction (%)

35

Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (solid line) (dashed line, 95% conﬁdence interval) showed no
relative treatment effect of omecamtiv with decreasing ejection fraction for the time-to-cardiovascular death (interaction p ¼ 0.25 by ejection fraction as continuous
variable) (A). Incidence rates (B) (events/100 patient-years) of cardiovascular death increased with decreasing ejection fraction in both the placebo (blue lines) and
omecamtiv mecarbil group (purple lines).

reductions in NT-proBNP with decreasing EF, with a

provided the ﬁrst opportunity to evaluate the effect

22% reduction of NT-proBNP at week 24 in the lowest

of improving cardiac function on outcomes in pa-

EF quartile (#22%). Patients with EF in the lowest

tients with HFrEF. Given its mechanism of action,

quartile had a relative risk reduction of 17% and an

there is biological plausibility to the hypothesis that

absolute risk reduction of 7.4 events per 100 patient-

patients with greater systolic dysfunction would

years (number-needed-to-treat for 3 years ¼ 11.8) for

derive greater beneﬁt. In the pre-speciﬁed subgroup

the primary composite endpoint.

analyses, EF was the most signiﬁcant variable to

IMPROVING CARDIAC FUNCTION WITH THE MYOTROPE

modify the treatment effect of omecamtiv mecarbil.

OMECAMTIV MECARBIL. Although multiple drugs have

INFLUENCE OF EF ON TREATMENT EFFECTS OF

been developed to improve inotropy (11), omecamtiv

OTHER DRUGS. Reviewing data from other contem-

mecarbil is the ﬁrst drug to speciﬁcally increase sys-

porary drug trials in patients with HFrEF, the rela-

tolic function by targeting the sarcomere without any

tionship between treatment effect and baseline EF

direct vascular, electrophysiological, or neurohor-

has been variable. In the 11,186 patients with heart

monal effects and without increasing mortality. It

failure and an EF #34% in sinus rhythm evaluated in

exerts this effect by selectively binding to myosin,

a patient-level meta-analysis of beta-blocker trials

stabilizing its lever arm in a primed position resulting

(15), beta-blocker therapy resulted in greater relative

in an accumulation of cardiac myosin heads in the

risk reductions in cardiovascular hospitalizations as

pre-powerstroke state prior to onset of cardiac

well as the combined endpoint of cardiovascular

contraction (4). This mechanism increases the num-

hospitalizations

ber of force generators (myosin heads) that can bind

decreasing baseline EF. This pattern was not as

to the actin ﬁlament and undergo a powerstroke once

evident for cardiovascular or all-cause mortality, and

the cardiac cycle starts without altering the car-

interestingly, there was no beneﬁcial effect of beta-

diomyocyte calcium transient. Intravenous ome-

blocker therapy noted in the patients in atrial ﬁbril-

camtiv mecarbil improved cardiac performance in

lation. In analyses incorporating data from the

early clinical studies (12–14), and as noted in the

PARADIGM-HF (Prospective Comparison of ARNI with

previous text, oral omecamtiv mecarbil increased

ACEI to Determine Impact on Global Mortality and

systolic function in patients with chronic HFrEF in

Morbidity in Heart Failure) and PARAGON-HF (Pro-

the COSMIC-HF trial (5,6). The GALACTIC-HF trial

spective

and

comparison

cardiovascular

of

death

Angiotensin
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T A B L E 3 Omecamtiv Mecarbil Treatment Effects from Baseline to Week 24 of Selected Vital Signs and Laboratory Values

EF #22% (n ¼ 2,246)

EF 23%–28% (n ¼ 2,210)

EF 29%–32% (n ¼ 2,026)

EF $33% (n ¼ 1,750)

p Value

þ1.6 (0.2 to þ3.3)

0.6 (2.3 to þ1.2)

þ0.3 (1.4 to þ2.0)

1.0 (2.8 to þ0.9)

0.10

Inpatient

þ4.9 (þ0.8 to þ8.9)

þ0.2 (3.7 to þ4.1)

þ4.8 (þ0.6 to þ8.9)

0.0 (3.9 to þ3.9)

0.33

Outpatient

þ0.7 (1.2 to þ2.6)

0.6 (2.5 to þ1.2)

0.8 (2.6 to þ1.1)

1.5 (3.5 to þ0.5)

0.12

0.9 (0.4 to 2.2)

0.6 (1.9 to 0.8)

0.6 (1.9 to 0.7)

1.2 (2.7 to 0.2)

0.038

KCCQ total symptom score

Systolic BP, mm Hg

1.6 (2.5 to 0.6)

1.7 (2.7 to 0.8)

1.9 (2.9 to 0.9)

1.1 (2.1 to 0.1)

0.62

0.01 (0.04 to 0.05)

0.01 (0.06 to 0.03)

0.01 (0.06 to 0.03)

0.02 (0.03 to 0.06)

0.87

Creatinine, mg/dl

0.01 (0.04 to 0.02)

0.01 (0.02 to 0.04)

0.01 (0.02 to 0.04)

0.02 (0.01 to 0.05)

0.22

NT-proBNP ratio

0.78 (0.71 to 0.85)

0.90 (0.83 to 0.98)

0.95 (0.87 to 1.04)

0.97 (0.89 to 1.06)

<0.001

Troponin I ratio

1.19 (1.11 to 1.27)

1.29 (1.21 to 1.38)

1.27 (1.18 to 1.36)

1.27 (1.18 to 1.37)

0.22

Troponin I, ng/l

5 (4 to 6)

4 (3 to 5)

4 (3 to 5)

3 (2 to 4)

0.055

Heart rate, beats/min
Potassium, mmol/l

Values represent treatment effects as evaluated by between-group differences of change from baseline to week 24 (95% conﬁdence interval). Troponin I assay had limit of
detection of 6 ng/l with an upper reference limit of 40 ng/l.
Abbreviations as in Table 1.

receptor

worse NYHA functional class and MAGGIC (Meta-

blocker Global Outcomes iN HF with Preserved Ejec-

Analysis Global Group in Chronic HF) score, more

tion Fraction) trials (16,17), there was no effect

recent pre-randomization heart failure event, greater

neprilysin

inhibitor

with

Angiotensin

modiﬁcation by EF on the treatment effect of sacu-

NT-proBNP concentrations, as well as higher heart

bitril/valsartan for heart failure events or cardiovas-

rates and lower systolic blood pressure. These char-

cular death in patients with EF #42.5%, with a trend

acteristics typically interfere with initiation and up-

toward less treatment beneﬁt on total heart failure

titration of guideline-directed medical therapy, and

hospitalizations

with

as was observed in other trials, there was also an

decreasing baseline EF in these patients. Similarly, in

increasing risk of heart failure hospitalizations and

the

cardiovascular

DAPA-HF

and

cardiovascular

(Dapagliﬂozin

and

death

Prevention

of

death

with

decreasing

EF

in

Adverse Outcomes in Heart Failure) trial, the treat-

GALACTIC-HF. Thus, these severely affected patients

ment effect of dapagliﬂozin on the primary outcome

with increasing risk are often least likely to receive or

and heart failure events in patients with an EF #35%

tolerate heart failure therapies.

mildly increased with decreasing EF, and then also

CLINICAL IMPLICATIONS OF THE MODIFYING EFFECT OF

had a decreasing treatment effect in patients with EF

EF IN GALACTIC-HF. In GALACTIC-HF, omecamtiv

of approximately #18% (18). In the VICTORIA (Ver-

mecarbil reduced the risk of heart failure events in

iciguat Global Study in Subjects with Heart Failure

patients with EFs no >35%. The current analysis

with Reduced Ejection Fraction) trial, which evalu-

demonstrates that this treatment effect increases

ated the effect of vericiguat on patients with HFrEF

with decreasing EF and suggests that patients with

and EF #45%, there was a decreased hazard ratio for

EFs approximately #30% are most likely to beneﬁt

the primary endpoint of time-to-ﬁrst heart failure

from this therapy. Additional analyses will need to be

hospitalization or cardiovascular death in the lower 2

performed to identify the patients with EFs >30%

EF quartiles (EF 24% to 29% and EF #23%) (19).

who may also derive beneﬁt. Although omecamtiv

DIFFERENCES IN BASELINE CHARACTERISTICS BY

mecarbil

EF SUBGROUPS. Different baseline characteristics,

consistent with the overall ﬁndings in GALACTIC-HF,

did

not

reduce

cardiovascular

death,

deﬁned by EF subgroup, have been noted in multiple

omecamtiv mecarbil had no adverse effect on blood

prior heart failure studies, including the CHARM

pressure, heart rate, potassium homeostasis, or renal

(Candesartan in Heart failure: Assessment of Reduc-

function when assessed by EF quartile. The small

tion in Mortality and morbidity) trials (20), the beta-

reduction in heart rate, believed to be due to the

blocker trials (15), PARADIGM-HF (16) and DAPA-HF

secondary effect of sympathetic withdrawal, was

(18). In GALACTIC-HF, patients with lower EFs were

consistent across the EF groups. As noted in prior

more likely to be younger, to be men, and to have a

trials, a minor increase in troponin I was noted across

nonischemic etiology of heart failure, whereas they

EF subgroups with no modifying effect by EF; how-

were less likely to have atrial ﬁbrillation, hyperten-

ever, there was no evidence of adverse clinical con-

sion, or diabetes mellitus. Patients with lower EF also

sequences (5,14). There was no difference in the

had indicators of more severe heart failure, such as

relative risk of treatment for emergent adverse
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T A B L E 4 Other Outcomes and Adverse Events of Special Interest

Safety Outcomes

EF #22% (n ¼ 2,246)

EF 23%–28% (n ¼ 2,210)

EF 29%–32% (n ¼ 2,026)

EF $33% (n ¼ 1,750)

Any treatment emergent
serious adverse events
Omecamtiv mecarbil

683 (60.7)

616 (56.9)

579 (57.3)

495 (55.5)

Placebo

719 (64.6)

666 (59.3)

585 (58.0)

465 (54.3)

0.94 (0.88–1.00)

0.96 (0.89–1.03)

0.99 (0.92–1.07)

1.02 (0.94–1.11)

Omecamtiv mecarbil

97 (9.8)

80 (8.3)

62 (6.9)

51 (6.4)

Placebo

99 (9.8)

85 (8.5)

65 (7.2)

55 (7.3)

1.00 (0.76–1.30)

0.98 (0.73–1.31)

0.96 (0.69–1.34)

0.88 (0.61–1.27)

Omecamtiv mecarbil

41 (3.6)

35 (3.2)

21 (2.1)

22 (2.5)

Placebo

46 (4.1)

35 (3.1)

27 (2.7)

19 (2.2)

0.88 (0.58–1.33)

1.04 (0.65–1.65)

0.78 (0.44–1.37)

1.11 (0.61–2.04)

Relative risk (95% CI)
Adverse event:
ventricular tachyarrhythmia

Relative risk (95% CI)
Serious adverse event:
ventricular arrhythmia
requiring treatment

Relative risk (95% CI)
Adjudicated ﬁrst major cardiac
ischemic events
Omecamtiv mecarbil

54 (4.8)

47 (4.3)

41 (4.1)

58 (6.5)

Placebo

45 (4.0)

49 (4.4)

38 (3.8)

56 (6.5)

1.19 (0.81–1.75)

1.00 (0.67–1.47)

1.08 (0.70–1.66)

0.99 (0.70–1.42)

34 (3.8)

Relative risk (95% CI)
Positively adjudicated
myocardial infarction
Omecamtiv mecarbil

37 (3.3)

29 (2.7)

22 (2.2)

Placebo

30 (2.7)

34 (3.0)

22 (2.2)

32 (3.7)

1.22 (0.76–1.96)

0.89 (0.54–1.44)

1.00 (0.56–1.79)

1.02 (0.64–1.64)

Relative risk (95% CI)
Adjudicated ﬁrst stroke
Omecamtiv mecarbil

17 (1.5)

19 (1.8)

24 (2.4)

16 (1.8)

Placebo

26 (2.3)

37 (3.3)

29 (2.9)

20 (2.3)

0.65 (0.35–1.18)

0.53 (0.31–0.92)

0.83 (0.48–1.41)

0.77 (0.40–1.47)

Relative risk (95% CI)

Values are n (%) unless otherwise indicated.
Abbreviations as in Tables 1 and 2.

events, tachyarrhythmias, or cardiac ischemic events

to multiplicity testing, the univariate interaction p

compared with placebo. Thus, therapy with ome-

value for the treatment-covariate interaction was

camtiv mecarbil could be initiated in appropriate

0.004 and was 0.009 after adjustment for all other

patients at any time in their clinical course without

pre-speciﬁed subgroups, making it highly unlikely to

interfering with the initiation or up-titration of life-

be due to chance. In addition, there is biological

saving guideline directed medical therapy.

plausibility for this effect modiﬁcation, and the
ﬁndings are internally consistent. Other potential

STUDY

LIMITATIONS. Although

of

limitations are that the EF was the investigator-

GALACTIC-HF by EF was pre-speciﬁed, subgroup

the

analysis

reported, the most recent value within 12 months

analyses have inherent limitations. Many subgroup

prior to randomization, and it was not measured by a

analyses have limited sample sizes and number of

core laboratory or immediately prior to randomiza-

events. The evaluation of EF by quartiles in the cur-

tion. Although this approach is more consistent with

rent analysis has subgroups of approximately 2,000

clinical practice, where EFs are measured in response

patients with 578 to 979 events in each quartile,

to speciﬁc clinical events, there is the possibility that

subgroups in themselves larger than many studies.

the reported EF is not reﬂective of the baseline EF at

These investigations are supported by analyses of EF

the time of enrollment. To mitigate this possibility,

as a continuous variable incorporating the data from

investigators were instructed to repeat the measure-

all 8,232 patients. Although the statistical analysis

ment if there had been an intervening event that

plan from GALACTIC-HF pre-speciﬁed multiple sub-

might have changed its value. This analysis only as-

groups for evaluation and is subject to issues related

sesses the inﬂuence of 1 variable, the baseline EF, on
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-

TRANSLATIONAL OUTLOOK: Further analyses could

DURAL OUTCOMES: In patients with left ventricular

identify patient characteristics other than EF that are

EF #35% receiving guideline-directed therapy, those

associated with greater clinical responsiveness to ome-

with more severe ventricular systolic dysfunction exhibit

camtiv mecarbil and deﬁne its place in the optimum

the greatest reductions in heart failure hospitalization or

sequence of pharmacological interventions for patients

cardiovascular death during treatment with the cardiac

with HFrEF of various etiologies.

myosin activator omecamtiv mecarbil.
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